Critical evaluation of the efficacy and tolerability of azilsartan
Vascular Health and Risk Management, 05/16/2012De Caterina AR et al.
The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre–clinical and clinical studies.
Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension.
Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached.
For this reason, the search for new antihypertensive agents is still ongoing.
Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.